JP6488276B2 - 天然化合物及び／又は食事を用いる癌の調節 - Google Patents

天然化合物及び／又は食事を用いる癌の調節 Download PDF

Info

Publication number
JP6488276B2
JP6488276B2 JP2016501388A JP2016501388A JP6488276B2 JP 6488276 B2 JP6488276 B2 JP 6488276B2 JP 2016501388 A JP2016501388 A JP 2016501388A JP 2016501388 A JP2016501388 A JP 2016501388A JP 6488276 B2 JP6488276 B2 JP 6488276B2
Authority
JP
Japan
Prior art keywords
cancer
tumor
mkd
hydrochloride
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016501388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514135A (ja
JP2016514135A5 (enExample
Inventor
レイノルズ，ブレント
デリーロール，ロイク
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド, ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド filed Critical ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド
Publication of JP2016514135A publication Critical patent/JP2016514135A/ja
Publication of JP2016514135A5 publication Critical patent/JP2016514135A5/ja
Application granted granted Critical
Publication of JP6488276B2 publication Critical patent/JP6488276B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/055—Organic compounds containing sulfur as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2016501388A 2013-03-14 2014-03-12 天然化合物及び／又は食事を用いる癌の調節 Expired - Fee Related JP6488276B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784386P 2013-03-14 2013-03-14
US61/784,386 2013-03-14
PCT/US2014/023934 WO2014159500A1 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018093204A Division JP2018162248A (ja) 2013-03-14 2018-05-14 天然化合物及び／又は食事を用いる癌の調節

Publications (3)

Publication Number Publication Date
JP2016514135A JP2016514135A (ja) 2016-05-19
JP2016514135A5 JP2016514135A5 (enExample) 2017-04-13
JP6488276B2 true JP6488276B2 (ja) 2019-03-20

Family

ID=51625178

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501388A Expired - Fee Related JP6488276B2 (ja) 2013-03-14 2014-03-12 天然化合物及び／又は食事を用いる癌の調節
JP2018093204A Pending JP2018162248A (ja) 2013-03-14 2018-05-14 天然化合物及び／又は食事を用いる癌の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018093204A Pending JP2018162248A (ja) 2013-03-14 2018-05-14 天然化合物及び／又は食事を用いる癌の調節

Country Status (9)

Country Link
US (2) US20160038456A1 (enExample)
EP (1) EP2968260B1 (enExample)
JP (2) JP6488276B2 (enExample)
CN (2) CN110420329A (enExample)
AU (3) AU2014240467B2 (enExample)
BR (1) BR112015023190A2 (enExample)
CA (1) CA2912518A1 (enExample)
IN (1) IN2015DE09621A (enExample)
WO (1) WO2014159500A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) * 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および／または規定食を用いた炎症の治療方法
CA2993773A1 (en) * 2015-09-04 2017-03-09 Osaka University Development of dietary therapy in cancer
RS62108B1 (sr) 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Antitelo-lek konjugati na bazi eribulina i postupci primene
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN108192866B (zh) * 2018-03-07 2021-05-11 郑州大学第一附属医院 Sfn联合il-15和il-21制备记忆性t细胞的方法及应用
KR102174166B1 (ko) * 2018-12-13 2020-11-04 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
CN110420178B (zh) * 2019-09-11 2022-08-05 长江师范学院 一种胭脂萝卜硫苷水凝胶的制备方法
EP3861992B1 (en) * 2020-02-07 2023-09-06 CannaFamily a.s. Combination therapy comprising plant derived compounds and antineoplastic compounds for treatment of hematological malignancies
PL4190173T3 (pl) * 2020-09-23 2025-01-07 Aminovita S.L. Metaboliczna terapia przeciwnowotworowa
TW202339712A (zh) * 2022-01-24 2023-10-16 國立大學法人大阪大學 用於治療癌症之組合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725895B1 (en) * 1995-09-15 2000-10-10 Hopkins J School Of Medicine Method of preparing food product from cruciferous seeds
US6242018B1 (en) * 1997-04-11 2001-06-05 Johns Hopkins School Of Medicine Cancer Chemoprotective food products
JPH1149793A (ja) * 1997-08-08 1999-02-23 Momoya:Kk 野菜由来の抗腫瘍性物質
CN1141092C (zh) * 2001-01-19 2004-03-10 郭兴华 一种防治骨质疏松、癌症和降血脂组合物及其应用
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
JP2007153834A (ja) * 2005-12-07 2007-06-21 Univ Kansai カイワレ大根由来の不凍活性を有する抽出物、その製造方法、ならびにその用途
WO2009051739A1 (en) 2007-10-16 2009-04-23 Johns Hopkins University Methods for protecting the skin from radiation insults
US20090252758A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
AR084174A1 (es) 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
DE102011008017A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Erfrischungsgetränk
DE102011008016A1 (de) 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
WO2012113415A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
WO2012122295A2 (en) 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
CA2831403A1 (en) * 2011-05-19 2012-11-22 Glax L.L.C. Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
GB201210699D0 (en) 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
JP6548573B2 (ja) 2012-07-05 2019-07-24 ニュートラマックス ラボラトリーズ，インコーポレイテッド スルホラファンまたはスルホラファン前駆体およびキノコ抽出物または粉末を含む組成物
US20140275235A1 (en) 2013-03-15 2014-09-18 Loic Pierre Deleyrolle Treatment of Proliferative Disorders
CA2904865A1 (en) 2013-03-15 2014-10-16 Nutramax Laboratories, Inc. Sulforaphane/sulforaphane precursor and phytosterol/phytostanol compositions
EP2976073B1 (en) 2013-03-19 2019-08-28 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
US10835566B2 (en) 2013-05-14 2020-11-17 Mars, Incorporated Joint care composition
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
WO2015034812A2 (en) 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および／または規定食を用いた炎症の治療方法

Also Published As

Publication number Publication date
EP2968260A4 (en) 2017-05-10
JP2016514135A (ja) 2016-05-19
AU2014240467B2 (en) 2018-11-29
US20160038456A1 (en) 2016-02-11
EP2968260A1 (en) 2016-01-20
JP2018162248A (ja) 2018-10-18
AU2019201369A1 (en) 2019-03-21
CN105377252A (zh) 2016-03-02
EP2968260B1 (en) 2020-12-16
CN110420329A (zh) 2019-11-08
AU2020223647A1 (en) 2020-09-10
WO2014159500A1 (en) 2014-10-02
CA2912518A1 (en) 2014-10-02
AU2014240467A1 (en) 2015-11-05
US11666549B2 (en) 2023-06-06
BR112015023190A2 (pt) 2017-07-18
US20210008024A1 (en) 2021-01-14
IN2015DE09621A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
JP6488276B2 (ja) 天然化合物及び／又は食事を用いる癌の調節
Du et al. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice
US11020372B2 (en) Dietary and natural product management of negative side effects of cancer treatment
JP6829723B2 (ja) ポリフェノール化合物を有効成分として含む癌治療用薬学組成物
KR20180087238A (ko) 혈액암에 대한 새로운 치료 전략
JP7673993B2 (ja) 癌の転移抑制および治療用組成物
Liu et al. Epigallocatechin gallate attenuates interstitial cystitis in human bladder urothelium cells by modulating purinergic receptors
JP2022529949A (ja) ミトコンドリア標的化及び抗癌治療のためのアルキルｔｐｐ化合物
JP2017535617A (ja) 中皮腫の処置において使用するためのシナラ・スコリムスの滴定抽出物
CN109640978A (zh) 以芹菜素、姜黄素及和厚朴酚为有效成分包含的肺癌预防或治疗用药学组合物
KR102349013B1 (ko) 멜라토닌을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
JPWO2014171333A1 (ja) ミトコンドリア活性化剤
CN101843606A (zh) 大黄素作为急性白血病化疗药物的增敏剂和多药耐药逆转剂的应用
JP7352275B2 (ja) 更年期症状改善用組成物
KR101184152B1 (ko) 항산화 단백질 엔알에프-2의 활성 증진, 간염 치료 및 예방 또는 간 보호에 유용한 3, 4-디히드록시벤잘아세톤
WO2020199973A1 (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
KR101800129B1 (ko) 암의 예방 또는 치료용 약학적 조성물
KR101613005B1 (ko) 항암제에 의해 유발되는 신장 독성 질환의 예방 및 치료용 약학적 조성물
CN110840877A (zh) 右旋地衣酸单独或联合紫杉醇在制备治疗和抗肺鳞癌药物上的应用
KR102144264B1 (ko) 익모 추출물을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
JP2015509967A (ja) 急性骨髄性白血病または慢性骨髄性白血病を治療するための新規組合せ物
KR20190139998A (ko) 대기 오염 관련 질환을 방지하기 위한 위타니아 솜니페라 추출물의 용도
Marin et al. Parthenolide has apoptotic and cytotoxic selective effect on B-chronic lymphocytic leukemia cells
US20150329824A1 (en) Z cells activated by zinc finger-like protein and uses thereof in cancer treatment
TWI384983B (zh) 一種木樨素用於製備治療或預防血癌的保健食品之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190225

R150 Certificate of patent or registration of utility model

Ref document number: 6488276

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees